Eagle’s Eye View: Can Apixaban be Used Safely in Patients With AF and End-Stage Kidney Disease?
In this week’s View, Dr. Eagle explores the associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. He then discusses a study that looks at stroke risk in women with atrial fibrillation. Finally, Dr. Eagle examines the DCM Precision Medicine Study of rare variant genetics and dilated cardiomyopathy severity.
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Anticoagulation Management and Atrial Fibrillation, Implantable Devices, Genetic Arrhythmic Conditions, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Heart Transplant, Mechanical Circulatory Support
Keywords: EaglesEyeView, Anticoagulants, Arrhythmias, Cardiac, Atrial Fibrillation, Embolism, Hemorrhage, Kidney Failure, Chronic, Primary Prevention, Renal Dialysis, Stroke, Vascular Diseases, Warfarin, Geriatrics, Risk Factors, Sex Characteristics, Cardiomyopathy, Dilated, Defibrillators, Implantable, Genetics, Heart-Assist Devices, Heart Transplantation
< Back to Listings